Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer by Hang Yuan et al.
RESEARCH Open Access
Clinical research of intraperitoneal
implantation of sustained-release
5-fluorouracil in advanced colorectal cancer
Hang Yuan, Bo’an Zheng and Shiliang Tu*
Abstract
Background: The objective of this study was to investigate the safety and long-term clinical effect of
intraperitoneal implantation of sustained-release 5-fluorouracil in patients with advanced colorectal cancer during
radical resection.
Methods: A total of 202 patients with advanced colorectal cancer undergoing radical operations were randomly
divided into an experimental group (98 cases, intraoperative intraperitoneal implantation of sustained-release
5-fluorouracil 600 mg as local chemotherapy) and a control group (104 cases, without local chemotherapy). The
clinical data of the two groups was compared including toxicity, complications, local recurrence rate, distant
metastasis, disease-free survival, and 1-, 3-, and 5-year survival rates.
Results: Both groups of patients were followed up for more than 5 years, the longest follow-up time was 7.5 years.
Bone marrow suppression, hepato-renal function, postoperative anastomotic leakage, pelvic effusion, incision
infection, the incidence of intestinal obstruction, venting time, and hospital stay after operation (days) between two
groups had no statistical significant difference. Locoregional recurrence and liver metastasis rate were decreased
significantly in experimental group (P = 0.04 and 0.04). Extensive peritoneal metastasis and other organ metastasis
rates had no significant difference between two groups. In the experimental group, 1-, 3-, and 5-year survival rates
were higher than in the control group (95.92 vs 87.50 %, 77.55 vs 64.42 %, and 56.12 vs 40.38 %), which had
significant difference. Disease-free survival (DFS) of the experimental group was higher than that of the control
group (χ2 = 5.00, P = 0.025).
Conclusions: Intraperitoneal implantation of sustained-release 5-fluorouracil is safe for advanced colorectal cancer
during radical resection, which can reduce locoregional recurrence rate and liver metastasis rate. The long-term
efficacy was reliable, and long-term survival and disease-free survival rate can be improved.
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Background
The incidence of colorectal cancer (CRC) tops the list
among malignant tumors, and its mortality is also very
high. Each year, nearly 1,000,000 new cases of CRC are
diagnosed and there are 500,000 deaths from CRC [1].
The incidence of CRC in China is lower than in the
Western world, but has been increasing in recent years
[2]. The primary treatment for CRC is resection of the pri-
mary tumor. However, the intra-abdominal recurrence
and liver metastasis are the leading causes of deaths in pa-
tients with advanced colorectal cancer after a primary op-
eration. The intra-abdominal recurrence is mainly due to
exfoliated cells in the peritoneal cavity, retroperitoneal
lymph nodes, and metastatic lesions in the peritoneum.
Intraperitoneal chemotherapy allows the direct reaction
between the drugs and the surface of the peritoneum
and the organs in the abdominal cavity; thus, the cancer
cells that have dropped from cancer tissues or other
small cancer cell clones can be effectively killed, which
in turn can prevent the local recurrence of CRC. Many
studies reported that intraperitoneal administration of
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chemotherapeutic agents to eliminate the cancer cells
can prevent tumor recurrence. Several agents used in
intraperitoneal chemotherapy include cisplatin, 5-FU,
hydroxycamptothecin, and slow-release Sinofuan [3–6].
5-fluorouracil (5-Fu) is the most common and effective
chemotherapy drug used to treat CRC. Characterized by
long action duration, reaching the maximum drug con-
centration in targeted lesions, reducing the systemic
toxicity, and absorption not through gastrointestinal
tract, sustained-release 5-Fu can reduce the drug loss
and maximize drug utilization.
In this research, sustained-release 5-Fu was implan-
tated in the peritoneum and para-aortic abdominalis; the
results indicated that intraperitoneal implantation of
sustained-release 5-Fu is safe for advanced CRC and




A total of 202 patients with advanced CRC who had
been treated in the Surgical Department of Coloproctology,
Zhejiang Provincial People’s Hospital between June
2007 and July 2008 were included in this study. The
ages of the patients ranged from 37 to 72 years. The
presurgical workup included physical examination, lung
CT scan, CT or MRI scan of the abdomen, carcinoem-
bryonic antigen serum level determination, white and
red blood cell counts, platelet count, prothrombin time,
and determinations of aspartate aminotransferase,
alanine aminotransferase, and serum creatinine.
The inclusion criteria were patients with (1) a radical
resection and presurgical stages II–IV by colposcopy,
ultrasound, CT scan, or MRI; (2) a diagnosis of CRC
confirmed by preoperative biopsy and postoperative
pathology report; (3) no serious liver and kidney dysfunc-
tion; (4) a primary treatment without any other chemo-
therapy or biologic therapy before the operation; and (5)
informed consent.
The exclusion criteria were patients with (1) unresect-
able distant metastasis, complete intestinal obstruction,
severe abdominal adhesion or infection, or emergency
operation; and (2) any condition which was unsuitable
for chemotherapy.
This study was approved by the ethics committee
of Zhejiang Provincial People’s Hospital. All included
patients provided informed consent.
Study design
In operations, when the surgeon confirmed patients can
be treated with radical resection, then patients were ran-
domly assigned into two groups by a computer-generated
random number table, namely group 1 (98 patients receiv-
ing surgery plus adjuvant intraperitoneal chemotherapy)
and group 2 (104 patients with surgery plus normal
saline).
All patients underwent conventional open operations.
No-tumor procedures (including applying incise drape
to the incisions, exploring the no-tumor regions prior to
exploring the tumor regions, minimizing touching of the
tumor, avoiding applying pressure to the tumor, and li-
gating the vessels around the tumors first) were per-
formed strictly to avoid iatrogenic planting and spread.
After the tumor had been removed and reconstruction
had been performed (without reconstruction in Miles or
Hartmann operation), 2000 to 2500 mL of distilled water
was used to rinse the abdominal cavity before it was
closed.
Implanting sustained-release 5-Fu (Sinofuan) for
intraperitoneal chemotherapy
The preparation process of the implanted sustained-
release 5-Fu (Sinofuan, Chinese Wuhu Zhongren
Pharmaceutical Co., Ltd., Batch Number: 20030615) was
as follows: first, 5-Fu particles (the diameter of particles
within φ0.1~0.5 mm) were put into the coating pan with
specially made coating after crushing and sieving (120
meshes) the active ingredients in 5-Fu on the clean
workbench; next, medically used polydimethylsiloxane
solution was sprayed into the coating pan a few times to
form the microcapsules with 5-Fu microsphere as the
core and silicone rubber as the envelope, mixed with
polydimethylsiloxane solution again after drying and
curing for 4 h at 50 °C, pressed into the mold (φ0.8 ×
4 mm), and put on the side to solidify for 24 h; at last, it
was dried for 4 h under 40 °C and 0.09 MPa and then
packaged after inspection and sterilization.
In group 1, before closing the abdomen, a 600-mg
sustained-release 5-Fu (Sinofuan) was implanted to the
tumor bed, the surface of retroperitoneum and about
2 cm distant to mesenteric vascular artery or abdominal
aorta in case of colon cancer or upper rectal cancer, and
in case of rectal cancer below the peritoneal reflection,
that was implanted to before sacrum, the side wall of
pelvic cavity and about 2 cm distant to mesenteric vas-
cular artery or abdominal aorta. While in group 2, no
chemotherapeutic agent was implanted in the abdominal
cavity.
Safety evaluation
The effects of the treatments on the recovery, abdominal
cavity, and functions of other organs were evaluated ac-
cording to the common toxicity criteria issued by the
National Cancer Institute (NCI-CTCAE v4.0). Complica-
tions including fever for more than 3 days, pulmonary
infection, and anastomotic leakage were recorded. In
addition, other parameters including gas passage time,
drug allergy, abdominal drainage volume, peritoneal
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irritation signs (including abdominal pain and pressing
pain), gastrointestinal toxic reaction (including vomit,
diarrhea, and hemorrhage), hematologic toxic reaction
(including white blood cell count, red blood cell count,
and platelet count before and 7 days after the operation),
renal toxicity (including elevation of blood urea nitrogen
(BUN) and creatinine), and hepatotoxicity (including ele-
vation of enzymes like alanine aminotransferase) were
also measured. Adverse events were reported according
to the National Cancer Institute common terminology
criteria for adverse events (NCI-CTCAE v3.0; http://
ctep.cancer.gov).
Follow-up
Patients were followed up after operation following the
National Comprehensive Cancer Network (NCCN)
guideline for colon and rectal cancer (version 1.2007;
www.nccn.org/patients) by clinical examination, carci-
noembryonic antigen level, lung CT scan, and ultra-
sound of the abdomen every 3 months. Colonoscopy
was done 1 year after surgery and then repeated every
1 year in 3 years.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statis-
tics for Windows version 18 (SPSS Inc., IBM Corporation,
USA). Quantitative data was described by means and
standard deviations, and analyzed by Student’s unpaired
t test between groups, whereas qualitative data was de-
scribed by proportions and analyzed by the Chi-square
test. Kaplan-Maier survival analysis was performed.
P < 0.05 was considered statistically significant.
Results
Patients’ characteristics
The patients’ characteristics in groups 1 and 2 are listed
in Table 1. No significant difference was found in age,
sex, pathological type, clinical stages, and operation
method between the two groups (P > 0.05). Thus, the
background data for all patients was relatively similar.
Eighteen cases of stage IV patients in gp1 contained 4
cases with liver metastasis, 10 cases with isolate periton-
eal or great omentum metastasis, and 4 cases with other
organ metastases. Sixteen cases in gp2 contained 6 cases
with liver metastasis, 7 cases with isolate peritoneal or
great omentum metastasis, and 3 cases with other organ
metastases.
Incidence of postoperative complications
Incidences of postoperative complications in two groups
are listed in Table 2. No significant difference was found
in postoperative fever, pulmonary infection, incision in-
fection, gas passage time, pelvic effusion, and peritoneal
irritation signs between the two groups (P > 0.05). Four
Table 1 Baseline clinical characteristics of the 202 patients
Parameter Group 1 Group 2 P value
Age (years) 57.4 ± 3.1 59.3 ± 2.3
Sex
Males 50 56
Females 48 48 0.69
Localization of tumor
Rectum 58 58












Low 22 24 0.85
Operation methods
Right hemicolectomy 24 28
Left hemicolectomy 10 14
Dixon operation 38 41
Miles operation 18 12
Combined liver metastasis resection 4 6
Other 4 3 0.75
The patients’ characteristics in group 1 and 2 are listed. No significant
difference was found in age, sex, pathological type, clinical stages, and
operation method between the two groups (P > 0.05). The background data
for all patients was relatively similar
Table 2 Postoperative complications and hospitalized days in
the two groups
Postoperative complications Group 1 Group 2 P value
Anastomotic leakage 4 4 >0.05
Pulmonary infection 4 5 >0.05
Incision infection 8 10 >0.05
Pelvic effusion 4 6 >0.05
Gas passage time (days) 3.2 ± 0.6 3.3 ± 0.4 >0.05
Hospital stay after operation (days) 14.5 ± 4.2 16.3 ± 3.9 >0.05
Incidences of postoperative complications in two groups are listed. No
significant difference was found in postoperative fever, pulmonary infection,
incision infection, gas passage time, pelvic effusion, and peritoneal irritation
signs between the two groups (P > 0.05). Four cases of anastomotic leakage
were found in each of the two groups, and no patient required
revision surgery
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cases of anastomotic leakage were found in each of the
two groups, and no patient required revision surgery.
One patient complained of abdominal pain 1 week after
operation excluding obstructions in group 1, which were
ultimately considered an adverse effect of the drug.
Toxic effects in the two groups
Toxic effects in two groups are listed in Tables 3 and 4.
When assessing hematologic toxicity, it was found that
there were no significant differences in parameters like
white blood cells (WBC) between the two groups
(P > 0.05). There was no significant difference in creatin-
ine, alanine aminotransferase (ALT), and gastrointestinal
toxic reactions between the two groups (P > 0.05). No con-
gestive heart failure was found in either group.
The post-operation treatment
In group 1, 82 patients received systemic chemotherapy
for postoperative adjuvant chemotherapy for at least
2 months, including 80 cases of FOLFOX4 chemother-
apy and 2 cases of XELOX chemotherapy, while 16 cases
had not received adjuvant chemotherapy. In group 2, 84
patients received systemic chemotherapy for postopera-
tive adjuvant chemotherapy at least 2 months, and all re-
ceived FOLFOX4 chemotherapy. All stage IV patients of
two groups received FOLFOX4 chemotherapy.
Long-term results
The median follow-up time was 70.1 months (range 62–
90 months). Four patients had anastomotic recurrence
post-operation in group 1 and 13 patients in group 2
(P = 0.04). Twenty-eight patients developed to liver metas-
tasis in group 1 and 44 patients in group 2 (P = 0.04).
Twelve cases had locoregional recurrence in group 1
and 20 cases in group 2 (P = 0.04), while there was no
significant difference in extensive peritoneal metastasis
and other organ metastases. The group-specific 5-year
overall survival (OS) rates were 56.12 % in group 1 and
40.38 % in group 2 (P = 0.03). These differences were
statistically significant (Fig. 1). In groups 1 and 2, 5-year
OS rates of stage IV patients were, respectively, 16.7 %
(3/18) and 12.5 % (2/16) (P = 0.09). Mean disease-free
survival (DFS) was 36 months in group 1. The 5-year
disease-free survival rates were 48.98 % in group 1 and
34.62 % in group 2 (P = 0.04). These differences were
statistically significant (Fig. 2). Tumor recurrences
(Table 5) were observed in 48 patients (51.02 %) in
group 1 and 68 (65.38 %) in group 2.
The colonic cancer group-specific 5-year OS rates
were 57.5 % in group 1 and 37.0 % in group 2 (P = 0.04).
These differences were statistically significant (Fig. 3).
Mean DFS was 42 months in group 1. The 5-year
disease-free survival rates were 47.5 % in group 1 and
26.1 % in group 2 (P = 0.02). These differences were statis-
tically significant (Fig. 4). The rectal cancer group-specific
5-year OS rates were 55.2 % in group 1 and 43.1 % in
group 2 (P = 0.11). These differences weren't statistically
significant (Fig. 5). Mean DFS was 42 months in group 1.
The 5-year disease-free survival rates were 46.6 % in group
1 and 41.4 % in group 2 (P = 0.36). These differences wer-
en't statistically significant (Fig. 6).
Discussion
The postoperative recurrence rate of gastrointestinal tu-
mors is very high, even more than 50 %, especially colo-
rectal cancer, which is mainly due to the presence of
postoperative peritoneal micrometastasis. The literature
has revealed that after primary lesion resection, the re-
sidual cancer cells are most sensitive to intraperitoneal
chemotherapy in 7 days, and hence, it is the best time to
kill residual cancer cells and micrometastases [7]. In
7 days after the surgery, it is improper for the patients to
receive the peripheral venous chemotherapy with severe
systemic reactions due to poor constitution and in-
completely healed incisions. In addition, systemic
chemotherapy is not an effective option because of its
low drug concentration at the tumor site and short
action duration.
This is the only study reported in English that evalu-
ates the safety and long-term effects of intraperitoneal
chemotherapy with sustained-release 5-FU (Sinofuan)
administered in operation. The implanted sustained-
release 5-Fu used in this study is the first long-term
sustained-release implant in China, whose active ingredi-
ent is 5-Fu. As a new sustained-release implant organic-
ally combining high-molecular polymers with good
Table 3 Toxic and adverse effects in the patients in the two groups (χ2 ± s)
Group WBC (109/L) ALT (μ/L) Cr (μmol/L)
Group 1 Preoperative 6.82 + 0.85 27.32 + 12.12 2.31 + 0.42
Postoperative (one week) 8.95 + 1.23* 38.54 + 10.65** 2.54 + 0.43***
Group 2 Preoperative 5.98 + 0.79 24.75 + 13.68 2.33 + 0.61
Postoperative (one week) 9.05 + 2.12* 41.04 + 21.23** 2.53 + 0.71***
Toxic effects in two groups are listed. When assessing hematologic toxicity, it was found that there were no significant differences in parameters like white blood
cell (WBC) between the two groups (P > 0.05). No significant difference in creatinine, alanine aminotransferase (ALT)
WBC white blood cell, ALT alanine aminotransferase, Cr creatinine
No significant differences between the two groups, *P > 0.05, **P > 0.05, ***P > 0.05
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histocompatibility and commonly used drugs recorded
in pharmacopeia, it can alter the pharmacokinetics and
route of administration, characterized by solid implants,
intraperitoneally controlled release, long release time,
and locally targeted administration [8]. Peritoneally
implanted sustained-release drugs have the following
characteristics. (1) Long duration: it can continuously
act for several days, months, and even several years. (2)
Slowly controlled release: the release of 5-FU is slowly
controlled which can reduce systemic toxicity. (3) Target
Table 4 Toxic and adverse effects in patients in the two study groups (according to NCI-CTCAE v3.0)
Parameter Group 1 Group 2
I II III IV V I II III IV V
WBC 4 2 1 0 0 5 1 0 0 0
Platelet count 1 1 0 0 0 2 0 0 0 0
Bleeding 0 0 0 0 0 0 0 0 0 0
Renal toxicity 0 0 0 0 0 0 0 0 0 0
Hepatotoxicity 1 1 0 0 0 2 1 0 0 0
Fever (post-operation >7 days) 3 0 0 0 0 2 1 0 0 0
Infection 9 3 0 0 0 12 2 0 0 0
Diarrhea 0 0 0 0 0 0 0 0 0 0
Vomiting 1 0 0 0 0 1 1 0 0 0
Constipation 0 0 0 0 0 1 0 0 00 0
Cardiac function 0 0 0 0 0 0 0 0 0 0
Pneumonia (X-ray) 4 0 0 0 0 4 1 0 0 0
Peripheral numbness 0 0 0 0 0 0 0 0 0 0
Allergic reaction 0 0 0 0 0 1 0 0 0 0
Abdominal ache (post-operation >7 days) 5 2 0 0 0 5 1 0 0 0
When toxic and adverse events were classified according to the NCI-CTCAE v3.0, there were no significant differences between the two groups. The most common
were 7 cases of abdominal ache in group 1 and 6 cases in group 2; 2 cases of hepatotoxicity in group 1 and 3 cases in group 2; and 12 cases of infection in group
1 and 14 cases in group 2. All of the reported events were grade I or II and therefore were mild or moderate
NCI-CTCAE National Cancer Institute common terminology criteria for adverse events
Fig. 1 Overall survival curves (group 1, black line; group 2, red line). The group-specific 5-year overall survival (OS) rates were 56.12 % in group 1
and 40.38 % in group 2 (p = 0.03). These differences were statistically significant
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administration: the drug concentrations can reach the
highest in the targeted area of lesions, but the total dos-
age is minimal to reduce the systemic toxicity. (4) Loss
reduction: it can effectively make use of drugs to avoid
hepatic first-pass effect [9–11]. Therefore, early applica-
tion of locally intraperitoneal sustained-release chemo-
therapy can keep a higher drug concentration and
longer action duration, consequently achieving the tar-
geted administration and reducing systemic toxicity.
Animal experiments showed that drug concentration of
intravenous administration in blood after 12 h was re-
duced to below the tumor inhibition concentration,
while the local fluorouracil sustained-release implants
after 240 h still remain a valid antitumor drug concen-
tration [12]. A previous study has estimated that chemo-
therapeutic drugs could eliminate the number of cancer
cells ten times when drug concentrations at the tumor/
target site are increased at one time point [13]. The re-
search results about sustained-release 5-Fu implantation
(Sinofuan) revealed that 10 days after implantation, the
drug concentrations in the peritoneum, lymphatic tissue,
and portal vein remained relatively high within 5 cm of
the implanted site [14].
The killing effect of most chemotherapy drugs de-
pends on time and concentration within a certain range,
whereas the efficiency of intraperitoneal chemotherapy
drugs depends not only on the drug concentration, but
also on the action duration. In conventional chemother-
apy, the aqueous solvent of the drug has a shorter action
duration in the intraperitoneum, usually 6~8 h. In
addition, the depth of chemotherapy drugs penetrating
into tumors is limited from the surface. The effect of
chemotherapy is greatly affected when the tumor is
more than 0.5 cm [15]. However, with a good penetra-
tion in the interstitial space and cell membrane, and a
certain affinity with tumor tissue, 5-Fu usually enters
into the cells through passive diffusion according to a
concentration gradient, and can form a higher drug con-
centration locally and act for a long time [16]. The lit-
erature has revealed that 5-Fu wrapped with adjuvant
has a good effect in intraperitoneal chemotherapy of gas-
tric cancer [17]. Besides, the efficacy of 5-Fu is positively
associated with its action duration [18, 19]. In general,
the release time of 5-Fu wrapped with adjuvant does not
exceed 1 day, whereas that of sustained-release 5-Fu im-
plantation lasts more than 10 days, which overcomes the
disadvantage of conventional chemotherapeutic drugs
with a short action duration [20, 21]. Such preparations
can also be easily placed at any site of residual tumors
during surgery and stably maintain a higher drug
Fig. 2 Disease-free survival curves (group 1, black line; group 2, red line). These differences were statistically significant. Mean disease-free survival
(DFS) was 36 months in group 1. The 5-year disease-free survival rates were 48.98 % in group 1 and 34.62 % in group 2 (P = 0.04)
Table 5 Sites of tumor recurrence
Sites of tumor recurrence Group 1 Group 2 X2 value P value
Locoregional recurrence 12/98 20/104 4.04 0.04
Liver metastasis 20/98 30/104 4.15 0.04
Extensive peritoneal metastasis 11/98 8/104 0.64 0.42
Other organ metastases 11/98 6/104 0.84 0.36
Sites of tumor recurrences were observed in 48 patients (51.02 %) in group 1
and in 68 (65.38 %) in group 2
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concentrations at the administered area for a long
time, being conductive to killing the residual tumors
not removed during surgery, micrometastasis, and in-
traperitoneal free cancer cells. In addition, the local ad-
ministration makes the systemic normal cells have less
load; thus, the toxicity of anticancer drugs is kept to a
minimum. Therefore, sustained-release 5-Fu implant-
ation is an ideal local intraperitoneal chemotherapy
preparation because of sustained-release and targeted
dual properties.
Fig. 3 Kaplan-Meier survival analysis (group 1, black line; group 2, red line). The colonic cancer group-specific 5-year overall survival (OS) rates were
57.5 % in group 1 and 37.0 % in group 2 (P = 0.04, significant difference). These differences were statistically significant
Fig. 4 Kaplan-Meier survival analysis. The colonic cancer group disease-free survival curve. Mean disease-free survival (DFS) was 42 months
in group 1. The 5-year disease-free survival rates were 47.5 % in group 1 and 26.1 % in group 2 (P = 0.02). These differences were
statistically significant
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Numerous clinical data indicate that the subclinical
implanted metastasis formed by invasion of tumors into
serosa or implantation of exfoliative cancer cells into the
abdominal cavity due to surgery is the leading cause of
postoperative local recurrence and liver metastasis in
portal system in malignant tumors of the abdominal
cavity [22]. A study has found that the detection rate of
peritoneal free cancerous cells comes up to 43~55 % in
patients with pancreatic cancer [23]. Both surgical pro-
cedure and stimulation can increase the exfoliation of
cancer cells, and metastasis of peritoneal exfoliated cells
will directly lead to the recurrence and death in patients
Fig. 5 Kaplan-Meier survival analysis. The rectal cancer group overall survival curve. The rectal cancer group-specific 5-year overall survival (OS)
rates were 55.2 % in group 1 and 43.1 % in group 2 (P = 0.11). These differences weren't statistically significant
Fig. 6 Kaplan-Meier survival analysis. The rectal cancer group disease-free survival curve. Mean disease-free survival (DFS) was 42 months in group
1. The 5-year disease-free survival rates were 46.6 % in group 1 and 41.4 % in group 2 (P = 0.36). These differences weren't statistically significant
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after curative surgery and very low 5-year survival rate
in patients with progressive colorectal cancer. The most
common malignant tumors in the abdominal cavity eas-
ily occur during peritoneal metastasis and liver metasta-
sis, whereas the postoperative conventional treatment
including systemic intravenous chemotherapy has a
very low efficiency [24]. Currently, intraperitoneal im-
plantation of sustained-release 5-Fu has been widely
used in clinics, but its safety and efficacy are still con-
troversial [13, 25].
This study evaluated the safety of sustained-release 5-
Fu implantation during surgery. The incidences of post-
operative complications had no significant difference.
When toxic and adverse events were classified according
to the NCI-CTCAE v3.0, there were also no significant
differences between the two groups. The relation of the
treatment to events reported as signs of poor tolerance
is not obvious. Because of sustained-release and targeted
dual properties, total dosage is minimal to reduce the
systemic toxicity.
Theoretically, the intraperitoneal route combines the
effect of intraportal chemotherapy on the liver with a
direct effect on the peritoneum and the resection site
[26]. The reduction in liver and locoregional recurrence
rates observed in our study supports the hypothesis that
intraperitoneal chemotherapy combines locoregional
and hepatic effects. Because systemic and intraperitoneal
routes of administration of adjuvant chemotherapy ap-
pear to have different targets and different times of ef-
fect, they appear well suited for combined use. About
2 weeks after operations in this study, patients received
systemic chemotherapy for postoperative adjuvant
chemotherapy according to the NCCN (National Com-
prehensive Cancer Network) guideline. It is believed that
the exfoliation of cancer cells and metastasis of periton-
eal exfoliated cells may be killed by Sinofu after surgery,
which is supported by the results of this study, in which
the group-specific 5-year survival rates and DFS im-
provement were observed and the difference were statis-
tically significant. It is observed that the 5-year survival
rates and DFS have been improved in colonic cancer,
not in rectal cancer. Maybe it was due to the different
prognosis and guidelines for management. Patients with
rectal cancers of stages II or IV received chemoradio-
therapy after the operation. Some biomarkers will also
have influence on the outcome. Microsatellite instability
(MSI) is a marker of prognosis and chemotherapeutic
response. The impact of MSI is different between colon
and rectal cancers. Because high-frequency MSI (MSI-H)
showed a poor response to 5-FU chemotherapy, the
treatment regimen may dilute the impact of MSI. This
discrepancy may be due to selection bias.
This study has some limitations. The relatively small
sample size and single centeredness of the present study
limited the statistical power of the study; the difference
in adjuvant chemotherapy has an impact on the out-
come. Thus, these findings should be interpreted with
caution, and further studies with larger sample sizes and
multi-center are warranted to validate our findings.
Conclusions
The findings of the present study showed that there
were no significant differences in the anastomotic leak-
age, postoperative gas passage time, and other complica-
tions (including incision infection, pulmonary infection,
and hospital stay after operation (days)) between the two
groups, suggesting that intraperitoneal implantation of
sustained-release 5-Fu (Sinofuan) did not increase the
risk of the operation. In addition, no significant differ-
ence was found while comparing hematologic toxicity,
renal toxicity, hepatotoxicity, and cardiac disease param-
eters before and at the seventh day after the operation,
in each of the two groups. The toxic and adverse events
were all graded as I or II according to NCI-CTCAE v3.0
and therefore were mild or moderate. The reduction in
anastomotic and pelvic recurrence rates were observed
in the present study, which also showed group-specific
5-year survival rates and 5-year DFS improvement, and
the difference between the two groups were statistically
significant. In this study, using sustained-release 5-Fu
implantation during the surgery shows good safety and
provides evidences for the prevention and treatment of
peritoneal and liver metastases in intraperitoneal malig-
nant tumors and further application of sustained-release
5-Fu in clinics.
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